Zacks Research Issues Pessimistic Estimate for BAX Earnings

Baxter International Inc. (NYSE:BAX) – Equities research analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Baxter International in a research report issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of $0.49 for the quarter, down from their prior estimate of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

Other research analysts have also issued research reports about the company. The Goldman Sachs Group initiated coverage on Baxter International in a research report on Wednesday, February 26th. They set a “buy” rating and a $42.00 price target on the stock. Argus upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. JPMorgan Chase & Co. reduced their target price on Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Friday, February 21st. Barclays lifted their target price on Baxter International from $39.00 to $41.00 and gave the stock an “overweight” rating in a research note on Monday, March 10th. Finally, Citigroup reduced their target price on Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $38.56.

Baxter International Stock Down 1.0 %

NYSE:BAX opened at $34.50 on Monday. The firm has a market capitalization of $17.65 billion, a price-to-earnings ratio of -26.95, a price-to-earnings-growth ratio of 0.93 and a beta of 0.60. Baxter International has a twelve month low of $28.34 and a twelve month high of $43.99. The stock’s 50 day moving average price is $32.66 and its two-hundred day moving average price is $33.90. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06. The firm had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%.

Baxter International Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 annualized dividend and a yield of 1.97%. Baxter International’s dividend payout ratio (DPR) is presently -53.13%.

Institutional Trading of Baxter International

Institutional investors have recently added to or reduced their stakes in the company. CoreFirst Bank & Trust bought a new stake in Baxter International in the 4th quarter valued at $26,000. Riverview Trust Co boosted its stake in Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 933 shares during the period. LRI Investments LLC lifted its position in shares of Baxter International by 60.8% during the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 590 shares during the period. CKW Financial Group lifted its position in shares of Baxter International by 100.0% during the 3rd quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier’s stock valued at $81,000 after acquiring an additional 1,100 shares during the period. Finally, Bruce G. Allen Investments LLC lifted its position in shares of Baxter International by 247.3% during the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after acquiring an additional 1,867 shares during the period. 90.19% of the stock is currently owned by institutional investors.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.